Skip to main content Back to Top
Advertisement

2/4/2020

Griseofulvin Oral Presentations

Products Affected - Description

    • Griseofulvin oral suspension, Cipla USA, 125 mg/5 mL, 120 mL bottle, 1 count, NDC 69097-0361-08
    • Griseofulvin oral tablet, Rising Pharmaceuticals, 500 mg, bottle, 30 count, NDC 64980-0186-03 - discontinued
    • Griseofulvin oral tablet, Rising Pharmaceuticals, 500 mg, bottle, 100 count, NDC 64980-0186-01 - discontinued
    • Griseofulvin oral tablet, Amneal, 125 mg, bottle, 100 count, NDC 00115-1724-01
    • Griseofulvin oral tablet, Rising Pharmaceuticals, 125 mg, bottle, 30 count, NDC 64980-0184-03 - discontinued
    • Griseofulvin oral tablet, Rising Pharmaceuticals, 125 mg, bottle, 100 count, NDC 64980-0184-01 - discontinued
    • Griseofulvin oral tablet, Rising Pharmaceuticals, 250 mg, bottle, 30 count, NDC 64980-0185-03 - discontinued
    • Griseofulvin oral tablet, Rising Pharmaceuticals, 250 mg, bottle, 100 count, NDC 64980-0185-01 - discontinued

Reason for the Shortage

    • Amneal did not provide a reason for the shortage.
    • Cipla did not provide a reason for the shortage.
    • Rising discontinued griseofulvin products.
    • Sandoz has griseofulvin tablets available.
    • Teva has griseofulvin suspension available.

Available Products

    • Griseofulvin oral tablet, Sandoz, 500 mg, bottle, 100 count, NDC 00781-5515-01
    • Griseofulvin oral suspension, Teva, 125 mg/5 mL, 120 mL bottle, 1 count, NDC 00472-0013-04

Estimated Resupply Dates

    • Amneal has griseofulvin 125 mg tablets on back order and the company cannot estimate a release date.
    • Cipla has griseofulvin 125 mg/5 mL suspension on back order and the company estimates a release date in April 2020.

Updated

Updated February 4, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created July 18, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins